10/09/2018
Does familiarity with the paper informed consent process mean that it is the best way? Think that there are no benefits to switching to eConsent? Read about some common myths and follow links to helpful resources.
-
On June 3rd, 2026, the International Council of Harmonisation’s final ICH Guideline for Good Clinical Practice (GCP) E6(R3) Annex 2 was adopted in step 4 of the ICH formal procedure. A reminder of ICH’s standardized five-step formal procedure of developing, adopting, and implementing of guidelines can be reviewed.
-
On March 9th, 2026, the US Food and Drug Administration (FDA) released a draft guidance “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection”. The guidance is intended to assist drug manufacturers of FDA regulated drugs or combination products who choose to respond to an FDA Form 483 Inspectional Observations (483).
-
In March 2026, the International Organization for Standardization (ISO) published the fourth edition of ISO 14155:2026, replacing the previous edition from 2020. This is the medical device global reference for GCP conduct that many regulatory authorities recognize. Clinical Pathways offers an ISO 14155 Comparison Tool to support you to do an impact analysis and plan updates to SOPs, templates and tools for your trials.
-
The US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) collaborated with the European Medicines Agency (EMA) to develop 10 Guiding Principles of Good AI Practice in Drug Development. They are intended to be a foundational basis for developing good practices with AI, addressing the unique nature of AI, as well as cultivating its future growth.
-
In addition to the launch of Elsa, in a press announcement on December 1, 2025, the FDA broadcasted the deployment of Agentic AI capabilities for their employees. Agentic AI is unique from LLM AI due to its capability to plan, reason, and execute multi-step actions in order to achieve a specific goal. This means it can be used to assist with more complex tasks.
The Department of Health and Human Services (HHS) Office for Human Research Protections (OHRP) and the Food and Drug Administration (FDA) have been harmonizing their regulations and guidances to reduce regulatory burden and enhance human subject protections.
Topic: Certified Copies and ALCOA-C: Essentials Post ICH GCP E6 R2 Addendum
Date: October 9, 2018
Time: 1:00 p.m. – 2:30 p.m. EDT
Duration: 90 minutes
Sponsored by: Life Science Training Institute
Webinar: Live interactive session and recorded (available for 30 days)
Sign-up here
SAM Sather, MS, BSN, CCRC, CCRA, Vice President of Clinical Pathways, LLC, will be speaking at the Association of Clinical Research Professionals (ACRP)’s September 17, 2018 event. This in-person event will cover tips for managing trials for sites and sponsors post ICH E6 (R2) addendum, and 1.0 ACRP continuing education credits are available.
Topic: Managing Issues that Matter for Sites and Sponsors/CROs Post-GCP E6 (R2)
When: Monday, September 17, 2018 - 5:30 p.m. – 7:30 p.m. EDT
Where: Mez Contemporary Mexican (map)
5410 Page Rd.
Durham, NC 27703
Hors d’oeuvres and non-alcoholic beverages provided. Cash bar available.
Register: Registration is through ACRP here
Topic: ICH E6 (R2): Impact and Action Planning for Site and Sponsor Teams
When: Thursday, September 26, 2018 - 6:30 p.m. – 8:00 p.m. EDT
Where: Cisco WebEx link provided after registration
Register: EventBrite (link)